# European Commission

Organization · id `cardio:org-european-commission` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ROR record 00k4n6c32](<https://ror.org/00k4n6c32>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 3 trials in this atlas.

## Technical summary

Sponsor class other. Matched to ROR record 00k4n6c32 by an exact name.

## The registry's words

- Sponsor name: European Commission
- Sponsor class: OTHER
- ROR name: European Commission

## Connected pages

- Sponsors: Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock (`cardio:ct-nct01927549`)
- Sponsors: Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria (`cardio:ct-nct02040441`)
- Sponsors: Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock (`cardio:ct-nct03813134`)

## Provenance

Content hash: d9ac3ac452326e2aabb48cd148696ad464d313218bf6b72d615c5353bc8c69ac
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
